ArticleAmerican journal of ophthalmology case reports2025
A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops.
Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The evidence-based indications of 0.1% topical tacrolimus in ophthalmology: a scoping review.Therapeutic advances in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We report a case where tacrolimus eye drops may have alleviated immune checkpoint inhibitor (ICI)-related conjunctivitis attributed to nivolumab. Observations: A 61-year-old female complained of conjunctival hyperemia and eyelid swelling in both eyes. The patient was previously undergoing treatment for gastric cancer with nivolumab, with the final dose administered one week before the first ophthalmology visit. Initially, the patient was diagnosed with allergic conjunctivitis, managed with 0.1 % fluorometholone eye drops, 4 times daily in both eyes, but the symptoms did not improve despite 27 weeks of treatment, ICI-related conjunctivitis was considered, and the patient was prescribed with, 0.1 % tacrolimus eye drops twice daily in both eyes. One week later, there was a remarkable improvement in the conjunctival symptoms. Three months after, the conjunctival hyperemia reduced and swelling disappeared in both eyes, and, the frequency of instillation was reduced to once daily. The condition remains in remission with 0.1 % tacrolimus eye drops applied once daily in both eyes. Conclusions: Tacrolimus eye drops may have played a role to suppress ICI-related conjunctivitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.